N-nitrosamines are a regulatory and industry hot topic and whilst the focus has been on marketed products rather than development portfolios, there is an impact on investigational medicinal product development and manufacture. This webinar, led by Paul Cummings, will discuss nitrosamine impurities including key considerations when developing an IMP, the risks of delaying a formal risk assessment and more.